Longitude Capital Partners V, LLC sold $75.2M of MANE (indirect holdings)

Longitude Capital Partners V, LLC sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11. Filed jointly with Longitude Venture Partners V, L.P. (10% owner).

Original reporting
SEC EDGAR · Longitude Capital Partners V, LLC, Longitude Venture Partners V, L.P.
Published Nov 13, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Bearish
medium confidence
Mentioned
$MANE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANEBearishLow
01

Why it matters

The transaction represents a material insider divestiture that may influence short‑term price action.

02

Market read

Insider sell of $75M could create downward pressure on MANE stock in the near term.

03

What to watch

Potential tax‑loss harvesting or liquidity needs of the seller, not necessarily a bearish signal.

Relevance 6/10Novelty 6/10Timing: after-market filing today

Background

SEC Form 4 filing by a 10% owner disclosing a $75.2M open‑market sale of MANE shares.

Company-level read

Ticker impact

$MANEBearishMedium confidence
Context

Form 4 filing shows Longitude Capital Partners V sold 500,000 shares of MANE for $75.2M, reducing its stake to 1.8M shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

A 10% owner offloading $75M of stock can be interpreted as a lack of confidence, prompting short‑term downside.

Market effects

Minimal; the sale is company‑specific and does not affect the broader sector.

None

None

Counterpoint

The sale could be a portfolio rebalancing unrelated to fundamentals, so the stock may hold steady.

Key entities

  • Veradermics, Inc.

    Company whose shares were sold.

  • Longitude Capital Partners V, LLC

    Seller and 10% owner.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.